Oculis
Founded Year
2017Stage
Reverse Merger | IPOTotal Raised
$93.42MAbout Oculis
Oculis develops topical treatments. The treatments are based on a Solubilizing Nanoparticle (SNP) technology that helps to formulate drugs as eye drops and their bioavailability in the eye tissues including both the front and the back of the eye. The company provides clients with technological advancement in ocular drug delivery. Oculis was founded in 2017 and is based in Lausanne, Switzerland.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Oculis Patents
Oculis has filed 12 patents.
The 3 most popular patent topics include:
- Colloidal chemistry
- Dosage forms
- Drug delivery devices
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/28/2021 | 11/8/2022 | Drug delivery devices, Dosage forms, Pharmacokinetics, Diseases of the eye and adnexa, Ophthalmology | Grant |
Application Date | 9/28/2021 |
|---|---|
Grant Date | 11/8/2022 |
Title | |
Related Topics | Drug delivery devices, Dosage forms, Pharmacokinetics, Diseases of the eye and adnexa, Ophthalmology |
Status | Grant |
Latest Oculis News
Sep 12, 2023
Sanofi alum Sibold named CEO at Madrigal Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst September 11, 2023 11:06 PM UTC Bill Sibold succeeded Paul Friedman as CEO of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL), which is developing therapies for non-alcoholic steatohepatitis. Sibold was most recently EVP, specialty care and president of the North America division at Sanofi (Euronext:SAN; NASDAQ:SNY), where he held roles for almost 12 years. Friedman, who became CEO in 2016, will continue as a board member; Sibold will also join Madrigal’s board. Robert Landry will retire as EVP, finance and CFO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in February 2024, after a decade at the company. Landry will be succeeded by SVP, Head of Accounting and Controller Christopher Fenimore, who joined Regeneron in 2003 as VP of financial planning and analysis. The company also announced that Marc Tessier-Lavigne retired as a board member on Sept.1, a day after he stepped down as Stanford's president. ... BCIQ Company Profiles
Oculis Frequently Asked Questions (FAQ)
When was Oculis founded?
Oculis was founded in 2017.
Where is Oculis's headquarters?
Oculis's headquarters is located at EPFL Innovation Park, Lausanne.
What is Oculis's latest funding round?
Oculis's latest funding round is Reverse Merger.
How much did Oculis raise?
Oculis raised a total of $93.42M.
Who are the investors of Oculis?
Investors of Oculis include European Biotech Acquisition Corp., Brunnur Ventures, Silfurberg, Novartis Venture Funds, Bay City Capital and 12 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
